Italian IVDs (in vitro diagnostics) growth sustained over the E1 billion mark:
This article was originally published in Clinica
Executive Summary
The Italian IVDs market grew by just over 2% in 2003, from euro1.097bn ($1.32bn) to euro1.121bn, and by more than 5% over the last five years, according to a report published by diagnostics and biomedical industry association Assobiomedica. The market segment that showed greatest growth was glycaemia self-monitoring kits, which has grown more than 10% since 1999, to euro219m. For further details of Assobiomedica's 2003 IVDs report and views from the association on the prospects for Italy's wider medical technology industry, see the next issue of Clinica.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.